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While all TLRs originally appeared to activate the same
signaling pathways to initiate the inflammatory re-Summary
sponse, recent studies have indicated that the functional
roles of TLR3 and TLR4 are more complex for severalWe have identified a subset of genes that is specifically
reasons. First, TLR4 has been shown to mediate theinduced by stimulation of TLR3 or TLR4 but not by
response to a wide variety of ligands other than lipopoly-TLR2 or TLR9. Further gene expression analyses es-
saccharide (LPS), including Gram-positive lipoteichoictablished that upregulation of several primary re-
acids, the cancer chemotherapeutic Taxol, and the Fsponse genes was dependent on NF-B, commonly
protein of RSV (Kurt-Jones et al., 2000; Medzhitov andactivated by several TLRs, and interferon regulatory
Janeway, 1998; Takeuchi and Akira, 2001; Takeuchi etfactor 3 (IRF3), which was found to confer TLR3/TLR4
al., 1999). More perplexing is the fact that TLR4/specificity. Also identified was a group of secondary
mice have been shown to have increased susceptibilityresponse genes which are part of an autocrine/para-
to infection by RSV, while no such finding has yet beencrine loop activated by the primary response gene
reported in models of bacterial infection (Haynes et al.,product, interferon  (IFN). Selective activation of
2001). Also, TLR3 and TLR4 have been shown to activatethe TLR3/TLR4-IRF3 pathway potently inhibited viral
NF-B in cells lacking MyD88, albeit with delayed kinet-replication. These results suggest that TLR3 and TLR4
ics (Alexopoulou et al., 2001; Horng et al., 2001; Kawaihave evolutionarily diverged from other TLRs to acti-
et al., 1999). Recent reports indicate that the newlyvate IRF3, which mediates a specific gene program
cloned TIR domain-containing molecule TIRAP/Mal mayresponsible for innate antiviral responses.
function as a second adaptor for TLR3 and TLR4 and
direct activation of downstream signaling molecules in
Introduction the absence of MyD88 (Fitzgerald et al., 2001; Horng et
al., 2001).
Challenge by invading pathogens has led multicellular Importantly, recent reports have described a role for
organisms to develop a number of defensive measures interferon regulatory factor 3 (IRF3) in the TLR4 signaling
for the recognition and clearance of infectious agents. cascade (Kawai et al., 2001; Navarro and David, 1999).
The innate immune system is capable of recognizing a IRF3 is an important transcriptional regulator of the anti-
wide variety of pathogens and rapidly induces a number viral immune response. Through an unknown mecha-
of antimicrobial and inflammatory responses. Toll-like nism, viral infection causes IRF3 to become phosphory-
receptors (TLR) play a critical role in innate immunity by lated and migrate to the nucleus where it participates
recognizing structurally conserved bacterial and viral in the activation of a complex positive feedback loop
components termed pathogen-associated molecular between Type I IFNs and IRF family members, leading
patterns (PAMPs) (Medzhitov and Janeway, 1998). Ten to induction of an antigrowth, antiviral response (Sato et
TLRs have been cloned in mammals, and each receptor al., 2001; Taniguchi et al., 2001; Taniguchi and Takaoka,
appears to be involved in the recognition of a unique 2002). TLR4-mediated nuclear translocation of IRF3 has
set of PAMPs. While the focus of many studies has been been shown to occur in a MyD88-independent fashion
and to induce binding to interferon-stimulated response
elements (ISRE) in vitro at 2 hr poststimulation (Kawai10Correspondence: genhongc@microbio.ucla.edu
11These authors contributed equally to this work. et al., 2001). However, the functional role of IRF3 in
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TLR3- or TLR4-induced gene expression remains largely (Figure 1B) demonstrate similarities in kinetics of induc-
tion and LPS specificity. Microarray studies on boneundetermined.
Interestingly, members of the tumor necrosis factor marrow-derived macrophages (BMMs) established that
IFN mRNA was also specifically upregulated by LPSreceptor (TNFR) family use pathways similar to those
utilized by TLRs to mediate quite different biological at 2 hr (S.D. and G.C., unpublished data).
effects. One TNFR, CD40, has been shown to be inti-
mately involved in the adaptive immune response (Foy LPS-Primary Response Genes Exhibit
et al., 1996). At the molecular level, we have found that TLR3/TLR4 Specificity
CD40 stimulation activates the NF-B, JNK, p38, and In order to understand the mechanism of selective gene
PI3K pathways (our unpublished data), while, function- activation by LPS, we conducted both Northern blot
ally, CD40 is required for germinal center formation and analysis and quantitative real-time PCR (Q-PCR), focus-
affinity maturation (Gordon and Pound, 2000). Currently, ing on the macrophage cell type. As an example of
the molecular mechanisms that differentiate TLR-medi- our quantification methods, RANTES gene induction is
ated innate and TNFR-mediated adaptive immune re- shown using Northern blot analysis (Figure 2A) and
sponses are unknown. Q-PCR (Figure 2B), which is used in all subsequent ex-
To understand the signaling specificities between the periments. Throughout this report, the use of equivalent
TLR and TNFR families, we used Genechip microarray amounts of template in all Q-PCR reactions was con-
technology and compared the gene expression profiles trolled for by measurement of 18S rRNA amplification,
of B-lymphocytes stimulated with CD40L and LPS. In except where noted. Cycloheximide treatment indicated
this report, we describe a set of genes that is specifically that RANTES (Figures 2A and 2B), IP10, IFN, IFIT1, and
induced by the activation of TLR3 or TLR4 but not TLR2, ISG15 (data not shown) induction is the direct result of
TLR9, or CD40. These genes, many of which have been primary signal transduction and did not require new
previously described as viral or interferon-inducible, protein synthesis. Similar results were seen in B cells
were further classified as primary or secondary re- (data not shown).
sponse genes. We demonstrate that the primary re- We then investigated the TLR specificity of gene ex-
sponse genes are coregulated by the NF-B pathway, pression in BMMs using specific agonists for TLR4 (lipid
which is common for both TLRs and TNFRs, and the A), TLR2 (peptioglycan), TLR3 (poly I:C), and TLR9 (CpG).
IRF3 pathway, which is responsible for TLR3/TLR4-spe- In order to account for differences in binding affinity and
cific gene activation. In addition, we show that several receptor expression, the concentrations of TLR ligands
secondary response genes important for host defense used for stimulation were titrated to produce roughly
are activated by autocrine/paracrine secretion of IFN. equivalent activation of the JNK pathway as determined
Activation of the TLR3/TLR4-IRF3 pathway potently in- by GST-c-Jun in vitro kinase assay (Figure 2C, upper
hibits the replication of murine herpesvirus 68 (MHV68), left). Activation of NF-B and the production of inflam-
demonstrating the functional significance of this path- matory cytokines are well-described for all known TLRs,
way in antiviral responses. Overall, we have described and we found that our panel of TLR ligands induced both
a signaling and gene expression network specific to IB, a direct target of the NF-B signaling pathway, and
TLR3 and TLR4, and we provide evidence that these the inflammatory cytokine TNF (Figure 2C, middle left,
receptors play a unique role in the early detection and lower left). However, only TLR3 or TLR4 stimulation led
inhibition of viral infection by the innate immune system. to the immediate early upregulation of IFN, IP10, and
RANTES, while minimal gene induction was observed
with TLR2- or TLR9-agonists (Figure 2C, right panels).Results
Interestingly, IFN was induced more potently by TLR3
than TLR4, while the chemokines IP10 and RANTESLPS Induces a Subset of Genes Previously
Characterized as “Interferon Regulated” were induced to roughly equivalent levels by stimulation
of either receptor. No gene induction was observed inWe have conducted a series of microarray experiments
to determine gene expression patterns in murine B cells response to lipid A in TLR4 null BMMs generated from
C57BL/10ScCr mice that carry a null mutation in thein response to activating stimuli such as LPS and CD40L.
While CD40L specifically upregulates genes involved in TLR4 gene (Qureshi et al., 1999) (data not shown).
A summary of five TLR3/TLR4-specific primary re-cell-cell communication and germinal center formation
(Dadgostar et al., 2002), hierarchical clustering and filter- sponse genes—IP10, RANTES, IFN, ISG15, and
IFIT1—is shown in Figure 2D. These genes have beening of the microarray data also revealed a set of genes
specifically induced by LPS, at least 19 of which have studied by other groups primarily in the context of viral
infection and interferon stimulation (IP-10 [Cole et al.,been previously classified as “interferon regulated.” Fig-
ure 1A depicts a partial list of LPS-specific genes using 2001; Ohmori and Hamilton, 1993; Proost et al., 2001];
RANTES [Lin et al., 1999a; Luther and Cyster, 2001;color-based gene expression changes of Affymetrix
probe sets with matching accession numbers, gene Wagner et al., 1998]; IFN [Taniguchi and Takaoka,
2002]; ISG15 [D’Cunha et al., 1996]; IFIT1 [Guo and Sen,names, and descriptions. For a more complete analysis
of microarray data, see Supplemental Data at http:// 2000; Smith and Herschman, 1996]). To identify common
elements that might mediate TLR3/TLR4-specific genewww.immunity.com/cgi/content/full/17/3/251/DC1.
Genes were hierarchically clustered using average dif- induction, we analyzed the gene promoters using the 5
1 kb sequence obtained from Celera proprietary murineference change values derived by comparing control
samples (media 4 hr) with samples from cells treated genomic databases and TESS promoter analysis soft-
ware (http://www.cbil.upenn.edu/tess/). The regulatorywith indicated stimulus. Line charts of selected genes
TLR3/4-Specific Gene Program
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Figure 1. LPS but Not CD40L Upregulates a Set of Genes Previously Characterized as Interferon Responsive
(A) Primary murine B cells were stimulated with LPS (20 g/ml) or a soluble CD8/CD40L chimera (300 ng/ml), and RNA was collected at
indicated time points and used to conduct microarray analysis. Genes previous characterized as interferon responsive were further subdivided,
and absolute expression changes were displayed using the Treeview Program. Expression changes: red, induced; green, repressed; black,
no change.
(B) Line charts display temporal expression pattern of selected genes from (A).
regions of all five genes showed high probability 2001; Navarro and David, 1999), it was recently reported
that LPS does not increase IRF3 transactivational activ-matches for ISRE and B consensus sequences (Max.
lg[td]  28.0) within a few hundred base pairs of the ity (Servant et al., 2001). As a result, the role of IRF3 in
response to PAMP-induced gene expression remains intranscriptional start site (Figure 2D). This indicated to
us that these genes may be coregulated by common question. Our promoter analyses led us to investigate
the activation of IRF3 and NF-B by TLR stimuli, asactivators which bind at these sites.
these transcription factors bind to ISRE and B consen-
sus sites, respectively. We first confirmed that TLR3-IRF3 and NF-B Are Involved in TLR3/TLR4-Mediated
Gene Activation and TLR4-agonists but not TLR2- or TLR9-agonists in-
duced rapid nuclear translocation of IRF3 (Figure 3A).Other groups studying models of viral infection have
demonstrated binding of IRF3 to the ISRE consensus However, unlike other reports, we found IRF3 to be acti-
vated within 15–30 min of treatment and to be insensitivemotifs in the promoters of IFN and RANTES (Lin et al.,
1999a; Wathelet et al., 1999). While LPS treatment can to cycloheximide treatment (data not shown). In addi-
tion, stimulation of TLR3 could induce faster and moreinduce the nuclear translocation of IRF3 and induce
ISRE binding in vitro at 2 hr of stimulation (Kawai et al., potent activation of IRF3 than TLR4, indicating further
Immunity
254
Figure 2. Characterization of TLR3/TLR4-Primary Response Genes
(A) RAW 264.7 macrophages were stimulated with LPS (100 ng/ml) for the indicated time points, and RNA was harvested and analyzed by
Northern blotting (left) using a cDNA probe for RANTES. CHX indicates 30 min pretreatment and costimulation with cycloheximide (20 g/
ml). Quantification of radioactive signal is depicted (right).
(B) Primary murine BMMs were stimulated with LPS (100 ng/ml) for the indicated time points, and RNA was harvested and then analyzed by
quantitative real-time PCR (Q-PCR) for RANTES (left) and 18S rRNA (right) expression. Experiments were conducted in triplicate. All Q-PCR
data in this report are represented as relative expression units unless otherwise indicated.
(C) BMMs were stimulated with the following TLR-agonists: lipid A (1 ng/ml), peptidoglycan (PGN) (20 g/ml), poly I:C (1 g/ml), or CpG (100
nM) for 30 min, and cell extracts were used for an in vitro kinase assay using GST-c-Jun as a substrate (upper left). Identical stimulations
were repeated for 1 hr, and RNA was harvested and used for Q-PCR analysis.
(D) Summary of TLR3/TLR4-primary response genes (see text for details).*, primary-reponse defined as upregulated by LPS (100 ng/ml) at 2
hr in the presence of cycloheximide (20 g/ml). φ, schematic representation of gene promoters created using Celera web-based murine
genomic database to obtain 5 regulatory region, followed by theoretical analysis using TESS promoter analysis software (http://www.cbil.
upenn.edu/tess/) and the TRANSFAC transcription factor database. Relevant consensus sequence matches are in accordance with published
literature. 	, induced synergistically by LPS and CHX. DC, dendritic cells; PBL, peripheral blood leukocytes.
functional divergence between these two receptors. immunoblotting nuclear and cytoplasmic fractions for
the resident proteins USF2 and tubulin, respectivelySimilar results were seen with 1 g/ml poly I:C (data not
shown). In contrast, we observed nuclear translocation (Figure 3B).
To determine whether IRF3 and NF-B were involvedof p65 in response to all TLR-agonists tested in BMMs
(Figure 3A) and RAW 264.7 macrophages (data not in the LPS-induced transcriptional activity, we con-
ducted chloramphenicol acetyl transferase (CAT) re-shown). Purity of cellular fractions was monitored by
TLR3/4-Specific Gene Program
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Figure 3. IRF3 and NF-B Are Involved in TLR3/TLR4-Mediated Gene Activation
(A) BMMs were treated for indicated time points with lipid A (1 ng/ml), peptidoglycan (PGN) (20 g/ml), poly I:C (10 g/ml), or CpG (100 nM).
Cells were fractionated, and 30 g of nuclear extract was analyzed by SDS-PAGE immunoblotting for IRF3 nuclear translocation followed by
stripping and reprobing for p65 and USF2.
(B) Purity of cellular fractionation was tested by immunoblotting for USF2 and tubulin.
(C) CAT reporter assay showing LPS-induced transactivation of the IP10 promoter. RAW 264.7 macrophages were transiently transfected
with 1 g of 243-IP10-pCAT and cotransfected with 6 g of pCDNA3 (mock), pEBB-IRF3-DBD, or pCDNA3-IBm-ER (IB-DA). Six hours
posttransfection, cells were treated with media or LPS (100 ng/ml) for 24 hr, and 30 g of protein was used for each CAT reaction. Results
are representative of three separate experiments.
porter assays in RAW 264.7 macrophages using the in RAW-IB-DA cells. These data provide evidence that
NF-B is required for the upregulation of LPS-primary5 243 segment of the murine IP10 promoter. We co-
transfected a dominant-negative mutant of IRF3 (IRF3- response genes. We then created RAW cell lines stably
expressing either full-length IRF3 or IRF3-DBD (FigureDBD) with a deletion of the N-terminal DNA binding
domain (133–420) (Lin et al., 1999b) and IB-DA 4C). Figure 4D shows Q-PCR analysis of gene expres-
sion in wild-type, IRF3, and IRF3-DBD RAW cells treated(pCDNA3-IBm-ER), a construct that encodes for a fu-
sion protein of the estrogen receptor and an undegrad- with LPS (100 ng/ml) (upper panels) or poly I:C (10 g/
ml) (lower panels). IRF3-overexpressing clones had bothable form of IB that we have previously shown provides
tamoxifen-inducible inhibition of NF-B (Lee et al., 1999). elevated basal and superinduction of several primary
response genes within 1 hr of stimulation, while IRF3-As shown in Figure 3C, LPS treatment potently induced
IP10 transactivation. However, this effect was inhibited DBD clones had inducible but reduced expression levels
as compared to wild-type. Similar results were seen forby both IRF3-DBD and IB-DA.
ISG15 and IFIT1 (data not shown). Remarkably, overex-
pression of IRF3 conferred TLR2 responsiveness toNF-B Is Required for Upregulation of Primary
Response Genes, While IRF3 Mediates TLR3/TLR4-specific genes (Figure 4E), indicating that
IRF3 may be sufficient for the specificity of gene expres-TLR3/TLR4 Specificity
In order to further determine the role of NF-B in LPS- sion observed. To demonstrate that IRF3 was not ex-
erting nonspecific effects, we analyzed IBgene induc-induced gene expression, we transfected RAW cells
with pCDNA3 (mock) or pCDNA3-IBm-ER (IB-DA). tion, a direct target of the NF-B signaling pathway. As
shown in Figure 4E (lower right), TLR2 stimulation withSingle-cell clones stably expressing these constructs
were generated by G418 selection and were screened PGN induced similar levels of IB in RAW-WT and
RAW-IRF3 cell lines. The integrity of Q-PCR analysesbased on inhibition of LPS-induced nitric oxide produc-
tion (M.E.H. and G.C., unpublished data) and lack of was controlled by -actin mRNA levels (data not shown).
These data support the conclusion that while NF-B isDNA binding activity by EMSA (Figure 4A). Figure 4B
shows that LPS stimulation (100 ng/ml) of RAW-mock required for TLR-dependent gene activation, IRF3 is the
principal component mediating the TLR3/TLR4 specific-cells induced rapid upregulation of IP10, IFN, and
RANTES. However, this was almost completely blocked ity of the primary response genes listed above.
Immunity
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Figure 4. NF-B Is Required for Activation of Primary Response Genes, While IRF3 Mediates TLR3/TLR4 Specificity
(A) RAW 264.7 clones stably expressing pCDNA3 (mock) or pCDNA3-IBm-ER (IB-DA) were treated for 30 min with LPS (100 ng/ml), tamoxifen
(200 nM), or both, and NF-B activity was assayed by EMSA.
(B) RAW-mock and RAW-IB-DA cell lines were pretreated with tamoxifen (200 nM) for 2 hr and were stimulated with LPS (100 ng/ml) for the
indicated time points. RNA was harvested and used for Q-PCR analysis.
(C) Stable expression of pEBB-IRF3 or pEBB-IRF3-DBD in RAW 264.7 cells was detected by Western blotting.
(D) RAW 264.7 macrophages expressing the IRF3 constructs in (C) were stimulated with LPS (100 ng/ml) or poly I:C (10 g/ml), and RNA was
harvested and used for Q-PCR analysis.
(E) RAW wild-type or IRF3-expressing macrophages were stimulated with PGN (20 g/ml), and RNA was harvested and used for Q-PCR
analysis.
Characterization of TLR3/TLR4-Secondary hr, while secondary response genes are induced from
2–6 hr. We focused on four genes—Mx1, IFI1, IFI204,Response Genes
In the course of our gene expression analysis, we found and IRF7—whose gene products are thought to be in-
volved in the development of innate immune responsesthat several genes initially screened were not induced
until 2 hr and were inhibited in the presence of cyclohexi- (Figure 5C) (Mx1 [Arnheiter et al., 1990]; IFI1 [Collazo et
al., 2001]; IFI204 [Gariglio et al., 1998; Johnstone andmide. Figure 5A shows an example of the induction
pattern of one secondary response gene, Mx1; CHX Trapani, 1999]; IRF7 [Sato et al., 2000; Taniguchi et al.,
2001]).treatment indicates that prior protein synthesis was re-
quired and that this gene is secondarily activated by a
LPS-induced protein. Similar results were seen for IFI1, TLR3/TLR4-Specific Production of IFN Activates
Secondary Response Genes Involved in Host DefenseIFI204, and IRF7, and the overall kinetics of activation
of these genes versus IFN (primary response) are Figure 6A demonstrates that TLR3- or TLR4-agonists
but not TLR2- or TLR9-agonists could induce upregula-shown in Figure 5B. IFN is highly upregulated at 1–2
TLR3/4-Specific Gene Program
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Figure 5. Characterization of TLR3/TLR4 Secondary Response Genes
BMMs were stimulated with LPS (100 ng/ml) for the indicated time points, and RNA was harvested and then analyzed by Q-PCR.
(A) Mx1 gene induction expressed in relative expression units.
(B) Kinetics of activation of IFN versus secondary response genes expressed as fold change (note: log scale).
(C) Summary of TLR3/TLR4 secondary response genes (see text for details). *, secondary-reponse defined as upregulated by LPS (100 ng/
ml) at 4 hr but blocked in the presence of cycloheximide (20 g/ml). φ, as demonstrated by studies in transgenic mice. N/D, not determined;
HIN, Hematopoietic Interferon-inducible Nuclear Protein.
tion of the secondary response genes. We also found shown). Notably, LPS 2 hr CM but not LPS alone could
also induce the rapid phosphorylation of STAT1 in 30that activation of TLR4 but not TLR2 or TLR9 induced
STAT1 phosphorylation (Figure 6B) and that this effect min, and this effect could be blocked by addition of anti-
IFN (Figure 6D). These data together demonstrate thatcould be blocked by treatment with cycloheximide (data
not shown). Type I IFNs (/) are known to induce the TLR4-specific upregulation of IFN can activate
STAT1 and is responsible for the secondary upregula-STAT1/ phosphorylation (Fu, 1992; Schindler et al.,
1992), and while IFN is clearly a primary response gene tion of Mx1, IFI1, IFI204, and IRF7.
(Figure 2C), we found that no significant upregulation
of IFN subspecies mRNA occurred until 4 hr as de- TLR3- and TLR4-Activation Inhibits
MHV68 Replicationtected by Q-PCR analysis (data not shown).
In order to investigate whether IFN was responsible As some of the secondary response genes activated by
TLR3 and TLR4 are known to play a role in viral resis-for the activation of our subset of secondary response
genes, we conducted experiments using the cell-free tance, we next sought to determine if these TLR ligands
could directly inhibit the replication of murine herpes-conditioned media (CM) of BMMs treated with TLR-
agonists for 2 hr. As shown in Figure 6C, treatment of virus 68 (MHV68). BMMs were simultaneously infected
with MHV68 (moi  5) and treated with various TLRfresh BMMs with LPS 2 hr CM resulted in rapid activation
of the LPS-secondary response genes within 30 min, as ligands (10, 1, or 0.1 ng/ml lipid A; 100 nM CpG; 10 g/
ml PGN; or 1, 0.1, or 0.01 g/ml poly I:C) for 48 hr,opposed to 2 hr of treatment with LPS alone (Figure 5B).
The addition of anti-IFN/ blocking antibodies but not and replication of viral proteins was then assayed by
Western blot analysis. Figure 6E demonstrates that ei-nonspecific rabbit IgG abolished this gene induction,
demonstrating that IFN in the CM was responsible for ther lipid A (lanes 4–6) or poly I:C (lanes 8–10) treatment
could significantly inhibit MHV68 replication in a concen-this effect. Similar results were seen for IRF7 (data not
Immunity
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Figure 6. TLR3/TLR4 Stimulation Induces Production of IFN and Activates Antiviral Responses
(A) BMMs were stimulated for the indicated time points with the following TLR-agonists: lipid A (1 ng/ml), PGN (20 g/ml), poly I:C (1 g/ml),
or CpG (100 nM), and RNA was harvested and used for Q-PCR analysis.
(B) BMMs were treated for indicated time points with the following TLR-agonists: lipid A (1 ng/ml), PGN (50 g/ml), or CpG (100 nM), and 20
g of protein extract was analyzed by SDS-PAGE immunoblotting using antibody specific for phosphorylated-STAT1 (Y701) or total STAT1.
(C) BMMs were treated for 30 min with cell-free conditioned media (CM) from BMMs treated for 2 hr with media or 100 ng/ml LPS in the
presence or absence of 20 g/ml blocking antibodies or nonspecific rabbit IgG (RIgG) as indicated. RNA was harvested and used for Q-PCR
analysis.
(D) STAT1 activation is blocked by anti-IFN. BMMs were treated for 30 min with CM as described in (C), and STAT1 phosphorylation was
then assayed as in (B).
TLR3/4-Specific Gene Program
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Figure 7. Model of TLR3/TLR4-Specific Antiviral Gene Program
Activation of TLR3 and TLR4 by poly I:C and LPS, respectively, induces the nuclear translocation of IRF3 and NF-B, which leads to the
upregulation of a set of primary response genes. IFN is one important cytokine that is produced, activates STAT1, and induces expression
of genes that can inhibit viral replication in uninfected cells.
tration-dependent manner, while PGN had a smaller ef- MHV68. Figure 6F shows that while media-treated con-
trol samples had significant amounts of viral proteinfect (lane 7), and CpG (lane 3) treatment was similar to
the media control. During infections performed in the (lane 2), only cells treated with CM from BMMs stimu-
lated with TLR3 or TLR4 ligands were able to suppresscontinuous presence of PGN, we repeatedly observed
a minor inhibition in MHV68 replication. This was true viral replication (lanes 3, 4, and 14). Neither PGN CM
nor direct treatment with PAMPs had a significant effectwhether BMMs were treated with 10 or 20 g/ml PGN,
and the inhibition was always considerably weaker than (lanes 5 and 21–24). Finally, inhibition of viral replication
by TLR3 and TLR4 ligands was specifically abolishedthat caused by either 1 ng/ml lipid A or 1 g/ml poly
I:C. These data indicate that among the TLRs tested, by addition of neutralizing antibodies to Type I IFN/
(lanes 6, 7, and 16). These data indicate that TLR3/TLR4-TLR3 and TLR4 are the strongest activators of genes
that play a role in resistance to viral infection. induced IFN mediates a functionally significant role in
the innate immune response to viral infection.We have shown that TLR3 and TLR4 can specifically
induce IFN and multiple downstream IFN response
genes. However, the functional relevance of this signal Discussion
and subsequent gene program were still undetermined.
We therefore designed experiments in which we pre- In this report, we have identified a specific subset of
genes induced by stimulation of TLR3/TLR4 and demon-treated NIH3T3 cells (which are hyporesponsive to
PAMP treatment) with the cell-free conditioned media strated that IRF3 and NF-B are key transcription factors
responsible for this gene expression. While NF-B was(CM) from BMMs stimulated with PAMPs for 3 hr. We
then assayed viral replication following 24 hr infection commonly activated by several TLRs, IRF3 was shown
(E) BMMs were infected with MHV68 (moi  5) and simultaneously treated with the indicated TLR ligands (100 nM CpG; 10, 1, or 0.1 ng/ml
lipid A; 10 g/ml PGN; or 1, 0.1, or 0.01 g/ml poly I:C). After 48 hr, cells were harvested and analyzed for MHV68 replication proteins by
immunoblotting using rabbit anti-MHV68 antibodies.
(F) NIH 3T3 cells were pretreated for 3 hr with conditioned media from BMM treated with LPS (100 ng/ml), lipid A (1 ng/ml), PGN (10 g/ml),
or poly I:C (1 g/ml) in the presence or absence of anti-IFN/ or nonspecific rabbit IgG (20 g/ml). Cells were then infected with MHV68
(moi  1) for 24 hr. MHV68 replication was assayed as described in (E). All results are representative of at least three separate experiments.
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to direct the specific induction of a set of primary and showed that while TLR4 induces IFN expression from
secondary genes involved in host defense. Activation 1 to 4 hr, TLR3 induces much higher levels of IFN with
of the TLR3/TLR4 signaling pathway was also found to extended kinetics, with maximal levels at 8 hr (S.A.V. and
potently inhibit viral infection by MHV68 through the G.C., unpublished data). This suggests that the TLR family
autocrine/paracrine production of IFN. Overall, we of receptors have evolved to exert a stimulus-specific
have described the signaling network that leads to the modulation of antiviral responses while retaining path-
automatic and sequential activation of specific genes ways common to all TLRs that lead to production of
in response to dsRNA or LPS/Lipid A—a TLR3/TLR4- proinflammatory genes such as TNF (Figure 2C).
specific antiviral gene program (Figure 7). These data While TLR4 can recognize some viral components, a
suggest that TLR3 and TLR4 have evolutionarily di- critical question still remains—how and why do bacterial
verged from other members of the TLR family and can products such as LPS activate this pathway? The role of
trigger important antiviral responses through activation IRF3 or IFN in bacterial infection is not well understood.
of IRF3. However, some recent reports have highlighted the abil-
Initially, our microarray data indicated that in B cells, ity of IFN to synergistically induce important compo-
LPS and CD40L activate many similar sets of genes for nents of the antimicrobial response such as iNOS and
overlapping biological functions, such as cell survival, IFN (Jacobs and Ignarro, 2001; Yaegashi et al., 1995).
proliferation, metabolism, and immunological isotype On the other hand, another report found that Type I
switching (data not shown). CD40L specifically upregu- interferons are associated with increased susceptibility
lated a subset of genes involved in cell adhesion, migra- to bacterial infection by Mycobacterium tuberculosis
tion, and germinal center formation (Dadgostar et al., (Manca et al., 2001). Clearly, more work must be done
2002), while LPS induced inflammatory cytokines (such to determine the true functional outcomes of TLR3/TLR4
as TNF, IL-1, and IL-6) and a subset of “interferon- activation.
associated” genes, as well as other poorly characterized While much is known about the biochemical events
genes with no previously described roles in TLR4 signal- downstream in the TLR signaling pathways, evidence of
ing (see Supplemental Data at http://www.immunity. increasing complexity between the individual receptors
com/cgi/content/full/17/3/251/DC1). Our data further has led to a renewed interest in the biological role of
confirm results observed in other published LPS-gene the TLRs. Few studies have been able to conclusively
expression studies. However, it is notable that the LPS- prove increased susceptibility to a natural pathogen in
specific genes listed in Figure 1A show remarkable over- TLR-deficient mice. However, the amazing detection ca-
lap with genes upregulated by viral infection as indicated pacities and evolutionary conservation of the TLRs
by viral gene expression studies (Geiss et al., 2001; Li strongly argue for an important functional role. Cur-
et al., 2001; Suzuki et al., 2000; Zhu et al., 1998). We rently, it is unclear exactly how TLRs bind their ligands
and others have also confirmed that some LPS-primary or cooperate with each other. It is possible that TLR3
response genes, such as IP10 and RANTES, are also and TLR4 may cooperate in the detection and response
secondarily upregulated by autocrine production of to certain viruses and may act separately or in conjunc-
IFN (data not shown) (Ohmori and Hamilton, 2001). tion with yet other TLRs to recognize other pathogens.
The specific activation of IRF3 by TLR3 and TLR4 led Further work is certainly required to clarify this question.
us to investigate gene expression with extensive titration Undoubtedly, activation of either TLR3 or TLR4 in-
of TLR-agonists. We found that increasing doses of PGN volves a much larger and more complex gene program
(25–50 g/ml) could induce mild upregulation of Type than illustrated in this report. However, our findings
I interferon through an IRF3-independent mechanism, show that these receptors can specifically activate sig-
particularly at later time points. However, TLR3/TLR4- naling pathways that render cells more resistant to viral
agonists at small doses (1 ng/ml LPS/lipid A or 1 g/ml infection. TLR ligands can exert both immunostimula-
poly I:C) caused more than a 50-fold increase in gene
tory and toxic effects in vivo, and the data presented
expression by 2 hr (data not shown). In addition, TLR2-
here identify distinct signaling pathways that lead to
and TLR9-agonists were unable to induce detectable
inflammatory or antiviral responses. The identificationIRF3 nuclear translocation at any concentration tested.
of a specific gene program that enhances innate antiviralWhile the nuances of regulation of each individual gene
activity may provide new directions for therapeutic treat-are unique and outside the scope of this paper, the
ments of viral infections. In addition, the developmentcontribution of IRF3 to the enhanceosomes of some of
of pharmacological drugs that would allow manipulationthese genes has been well documented in models of
of such a gene program might allow us to enhanceviral infection (Lin et al., 1999a; Wathelet et al., 1999).
the innate immunity in conditions where the adaptiveActivation of IRF3 after viral infection has been shown
immune system is compromised.to be the first step in activation of a “gene program”
that includes a positive feedback loop of Type I IFNs Experimental Procedures
and IRF family members (Taniguchi et al., 2001). Interest-
ingly, while the data presented here indicate that TLR3 Microarray and Clustering Analysis
B cell isolation, target preparation, and hybridization using Affyme-and TLR4 activate gene expression by a similar mecha-
trix Mu6500 microarrays were performed as described previouslynism at early time points, several lines of evidence sug-
(Dadgostar et al., 2002). Differential expression data was analyzedgest that even these receptors diverge with respect to
by Affymetrix Microarray Suite 4.0 software. Average difference changetheir activation of innate antiviral responses. Specifi-
values were then normalized, and the genes were clustered by the
cally, TLR3 induced a stronger activation of IRF3 (Figure uncentered correlation average linkage hierarchical clustering algo-
3A), and this correlated with higher levels of IFN (Figure rithm using Cluster. Data were then visualized as a dendogram using
Treeview software (http://rana.lbl.gov/EisenSoftware.htm).2C). Gene expression profiles from longer stimulations
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Cell Culture and Reagents STAT1 and c-Jun were obtained from Cell Signaling Technologies.
IFN blocking experiments employed an anti-IFN antibody (R&DMurine BMMs were differentiated from marrow from 6- to 10-week-
old C57B/6 mice as previously described (Chin et al., 2002). BMMs Systems), anti-Type I IFN/ (Access Biomedical, Inc.), or nonspe-
cific Rabbit-IgG (Sigma) at final concentrations of 20 g/ml. Cellswere maintained in 1
 DMEM, 10% fetal bovine serum, 1% penicil-
lin/streptomycin, and 30% L929 conditioned medium, and purity were lysed in modified RIPA buffer, extracts were quantitated using
either the Bradford assay reagent (Bio-Rad) or the BCA Proteinwas assayed to be 94%–99% CD11b. The RAW 264.7 murine mac-
rophage cell line (ATCC: TIB-71) was maintained in 1
 DMEM with Quantitation kit (Pierce), and 20 g of protein was loaded in each
lane and separated by SDS-PAGE. Gels were transferred to nitrocel-10% fetal bovine serum and 1% penicillin/streptomycin. In order to
study TLR activation, we used the following: 055-B5 E. coli LPS lulose filters and immunoblotted using the antibody manufacturers’
recommended instructions. For detection of MHV68, rabbit anti-(Sigma), F-583 E. coli lipid A (Sigma), S. aureus peptidoglycan
(Sigma), CpG oligonucleotides (Invitrogen), poly I:C (Pharmacia), MHV68 was used as described by Wu et al. (2001). To detect activa-
tion of JNK following TLR activation, in vitro kinase reactions wereand cycloheximide (Sigma). The dosage of poly I:C used was low-
ered from 10 g/ml to 1 g/ml for long-term experiments to ensure performed as previously described (Dadgostar and Cheng, 2000).
EMSA was done as previously described (Lee et al., 1999).viability of treated cells.
Virus Production, Infection, and HarvestingRNA Quantification
Murine herpesvirus 68 (MHV68) was produced and titered as pre-RNA was isolated for both Northern blotting and quantitative real-
viously described (Wu et al., 2001). For infection of macrophages,time PCR (Q-PCR) using a standard guanidium isothiocyanate
cells were simultaneously treated with PAMPs and infected withmethod. Northern blotting was done as previously described (Lee
MHV68 at an moi of 5. Following an incubation period of 48 hr, cellset al., 1999) and was hybridized using a RANTES cDNA fragment
were lysed in Laemmli buffer and 10% of total volume was subjected(IMAGE Clone: 832342, Research Genetics). For Q-PCR, RNA was
to SDS-PAGE, transferred to nitrocellulose, and MHV68 proteinsquantitated and 2 g of RNA was reversed transcribed using Super-
detected by Western blotting.script II (Invitrogen) according to the manufacturer’s instructions
For NIH3T3 experiments, macrophages were first treated withwith either oligo-dT or random hexamer as primers. Q-PCR analysis
PAMPs in the presence or absence of anti-Type I IFN/ (Accesswas done using the iCycler thermocycler (Bio-Rad). Q-PCR was
Biomedical, Inc.), or nonspecific rabbit-IgG (Sigma) for a period ofconducted in a final volume of 25 L containing: Taq polymerase,
3 hr. Conditioned medias were then collected and used to treat1
 Taq buffer (Stratagene), 125 M dNTP, SYBR Green I (Molecular
NIH3T3 cells for another 3 hr. Cells were then infected with MHV68Probes), and Fluoroscein (Bio-Rad), using oligo-dT cDNA or random
at an moi of 1. Following an incubation period of 24 hr, cells werehexamer cDNA as the PCR template. Amplification conditions were:
harvested and processed for viral content as described above.95C (3 min), 40 cycles of 95C (20 s), 55C (30 s), 72C (20 s). The
following primers were used to amplify a specific 100–120 bp
fragment of the following genes: RANTES 5, GCCCACGTCAAGGAG Acknowledgments
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